Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ACTRN12626000704392) titled 'A Phase II study of elranatamab in newly diagnosed systemic light-chain (AL) amyloidosis' on June 12.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Type of endpoint: Safety/efficacy
Primary Sponsor: Australasian Myeloma Research Consortium
Condition:
Amyloidosis
Amyloidosis
Blood - Haematological diseases
Intervention:
This is a phase II single arm clinical study.
Elrantamab will be administered by hospital staff and is given subcutaneously. Each treatment cycle is 28 days and maximum number of treatment cycles is 6. Treatm...